2021 American Transplant Congress
Comprehensive Utilization of HCV Viremic and Non-Viremic Donor Livers and Kidneys into HCV-negative Patients
Transplant Institute, Loma Linda University Health, San Bernardino, CA
*Purpose: We report our experience on virologic and graft outcomes of HCV-negative patients transplanted with HCV NAT+ (viremic) and HCV Ab+/NAT- (non-viremic) livers and kidneys…2021 American Transplant Congress
Excellent Outcomes of Kidney Transplantation from Hepatitis C Infected Donors
UVA Health System, University of Virginia, Charlottesville, VA
*Purpose: Utilization of Hepatitis C viremic (HCV D+) kidney donors in HCV naïve recipients has increased in the United States. While there are shorter waiting…2020 American Transplant Congress
Financial Analysis of Donor HCV+ Kidney in HCV- Recipients
*Purpose: Use of organs from viremic hepatitis C positive donors (dHCV+) in recipients without HCV has been demonstrated to improve access to kidney transplant (KTx).…2020 American Transplant Congress
A Follow-Up Over Time to the Impact of Reactive Anti-HCV and HCV NAT
LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK
*Purpose: A previous review from one U.S. organ procurement organization (OPO) concluded positive HCV test results yielded high rates of authorized/not recovered donors (ANR), low…2020 American Transplant Congress
Hepatitis C Antibody Seroconversion after Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
*Purpose: We aimed to assess factors associated with hepatitis C virus (HCV) seroconversion among HCV seronegative kidney transplant candidates receiving HCV infected donor kidneys.*Methods: This…2020 American Transplant Congress
Racial Differences in Acceptance of Public Health Service (PHS) Increased Risk Kidneys and Hepatitis C (HCV) Nat Positive Kidneys
Tulane University, New Orleans, LA
*Purpose: PHS increased risk kidneys and HCV NAT positive kidneys represent a significant proportion of the donor pool however, acceptance demands explicit patient consent that…2020 American Transplant Congress
Socio-Demographic Disparities in Access to Organs from HCV-Viremic Donors among HCV-Negative Patients
*Purpose: The success of pilot trials of transplanting organs from hepatitis C virus (HCV) viremic donors into HCV-negative recipients (HCV D+/R-) has led to an…2020 American Transplant Congress
Contract a Virus to Save a Life: A Comparison of Short Term Outcomes between Adult Hepatitis C Negative Kidney Transplant Recipients Receiving a Hepatitis C NAT Positive versus Hepatitis C Negative Deceased Donor Kidney
1Vanderbilt University, Nashville, TN, 2Drexel University, Philadelphia, PA
*Purpose: The United States opioid use epidemic over the past decade has coincided with an increase in hepatitis C positive (HCV+) kidney donors. Our aim…2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…2020 American Transplant Congress
HCV-Positive Donors Are Healthier and Inequitably Utilized in the United States
Liver Disease, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Increased utilization of HCV-positive (HCV+) liver allografts has been endorsed as a solution to the national organ shortage. Due to the opioid epidemic, there…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 28
- Next Page »